news

  • 14 May 2019
    Sienna Biopharmaceuticals announces SNA-120 (0.05%) biopsy data demostrate positive impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis

    Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced biopsy data from its recent Phase 2b clinical trial with SNA-120 (pegcantratinib), the Company’s Phase 3 topical, non-steroidal Tropomyosin receptor kinase A (TrkA) inhibitor under investigation for the treatment of psoriasis. Biopsy analyses were conducted at The Rockefeller University on 22 subjects, and included Immunohistochemistry (IHC), MicroArray and quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR). 

    “The clear and substantial impact by Sienna’s SNA-120 on immune cells and the vast array of important psoriasis-related pathways after 12 weeks of treatment is impressive and encouraging for a topical, non-steroidal treatment,” said James G. Krueger, D. Martin Carter Professor in Clinical Investigation, Director, Milstein Medical Research Program, and Senior Attending Physician at the Laboratory for Investigative Dermatology, The Rockefeller University.

    • Specifically, the Immunohistochemistry analysis showed meaningful and statistically significant improvement in the epidermal thickness at Week 12, supporting the effect of SNA-120 (0.05%) on keratinocyte hyperproliferation and inflammation. In addition, the data demonstrated a statistically significant reduction in T cell and dendritic cell counts, confirming an immune response to treatment with SNA-120.  
       
    • In MicroArray analyses, SNA-120 (0.05%) was also observed to affect most of the key inflammatory pathways in psoriasis (40 of 45) in a statistically significant manner when compared to vehicle at Week 12.
       
    • In the qRT-PCR analysis, SNA-120 (0.05%) demonstrated substantial, statistically significant gene expression improvements in key cytokines that play an important role in psoriasis pathogenesis, including IL-23, IL-12, IL-17A and IFNg, among other cytokines, in PASI 75 responders and even led to restoration to non-lesional expression levels, further validating the strong pharmacological effect of SNA-120.

    “We are pleased to report these histological and biomarker results from our recent Phase 2b trial with SNA-120, our tissue-targeted TrkA inhibitor,” said Paul F. Lizzul, M.D., Ph.D., Chief Medical Officer of Sienna. “These data showing SNA-120 affects key cytokines involved in psoriasis, including IL-17 and IL-23, continue to support and corroborate the mechanism of action of SNA-120 and the unique contribution of neurogenic inflammation to psoriasis pathogenesis. This impact of SNA-120 on validated targets of the most effective biologic therapies today, combined with the clinically meaningful effects observed in patients in the Phase 2b trial, further bolsters our excitement and confidence as we progress toward Phase 3 pivotal trials.”